百济神州北京招聘

BeiGene, publicly listed on NASDAQ (Ticker: BGNE), is a globally oriented biopharmaceutical company committed to emerging as a pioneer in the creation and advancement of innovative, targeted and immunotherapy treatments for cancer. Utilizing its cancer biology platform, BeiGene emphasizes the significance of the interaction between tumors and the immune system, and underscores the importance of primary tumor biopsies in the development of novel cancer models. The company boasts a multinational workforce exceeding 200 members, encompassing over 150 researchers and medical professionals, alongside a distinguished scientific advisory board. This board features eminent scientific expertise, extensive pharmaceutical industry knowledge, and a shared dedication to enhancing the lives of cancer patients worldwide.

BeiGene's clinical portfolio comprises pioneering oral small molecule therapies and monoclonal antibodies (mAbs) for cancer, notably including an anti-PD-1 mAb, a best-in-class BTK inhibitor, a RAF dimer inhibitor, a leading PARP inhibitor, and various combination clinical trials. Furthermore, the company's robust preclinical research initiatives are anticipated to yield additional small molecule and mAb candidates for clinical development in the near future.

For comprehensive details, please visit BeiGene's official website at www.beigene.com.